Investors
Announcements 2020
Glenmark Pharmaceuticals receives ANDA final approval for Tadalafil Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg; and receives ANDA tentative approvals for Gabapentin Enacarbil Extended-Release Tablets, 300 mg and 600 mg and Apremilast Tablets, 10 mg, 20 mg and
Glenmark becomes the first company to launch Remogliflozin + Vildagliptin fixed dose combination, at an affordable price for adults with Type 2 Diabetes in India
Glenmark Pharmaceuticals and Menarini enter into Exclusive Licensing Agreement for commercializing Ryaltris™ Nasal Spray across numerous markets throughout Europe.
Glenmark Pharmaceuticals receives ANDA tentative approval for Dabigatran Etexilate Capsules, 75 mg, 110 mg, and 150 mg
Glenmark Pharmaceuticals receives ANDA tentative approval for Axitinib Tablets,1 mg and 5 mg
Glenmark to divest select Anti-Allergy brands to Dr Reddy’s in Russia, Ukraine, Kazakhstan and Uzbekistan in anticipation of its ‘Ryaltris’ Launch
Credit Rating by S&P Global Ratings
Recently published data on Favipiravir as treatment for mild to moderate COVID-19 demonstrates significant improvement in time to clinical cure
Glenmark Pharmaceuticals receives ANDA approval for Tacrolimus Capsules USP, 0.5 mg, 1 mg and 5 mg
Newspaper Publication of Q2 FY 2020-21 Result
Glenmark’s consolidated revenue increased by 4.88 % to Rs. 29,524.79 mn for Q2 FY 2020-21
Glenmark’s MDA Q2 FY 2020 – 21
Glenmark’s Q2 FY 2020-21 Results
Board Meeting Newspaper Advertisement – November 6, 2020
Q2 FY21 Earnings Call Invitation – November 9, 2020
Board Meeting Intimation – 6th November, 2020
Glenmark Pharmaceuticals receives ANDA approval for Sirolimus Tablets, 0.5 mg, 1 mg and 2 mg
Glenmark introduces NINDANIB (Nintedanib) for the treatment of Pulmonary Fibrosis in India
Glenmark announces results of its “FAITH” combination trial
Transcript of the 42nd AGM
Proceedings and Scrutinizer's Report of the 42nd AGM
Chairman’s Speech at the 42nd AGM
42nd AGM Notice – Newspaper Advertisement
Newspaper Advertisement of 42nd Annual General Meeting
Glenmark AGM Notice 2020
Newspaper Publication of Q1 FY 2020-21 Result
Glenmark’s consolidated revenue grew by 0.94 % at Rs. 23,447.87 Mn. for Q1 FY 2020-21
Glenmark’s MDA Q1 FY 2020 – 21
Glenmark’s Q1 FY 2020-21 Results
Board Meeting Newspaper Advertisement – 14th August, 2020
Board Meeting Intimation – 14th August, 2020
Q1 FY21 Earnings Call Invitation – August 17, 2020
Credit Rating by Fitch Ratings
Notice to Shareholders for transfer of shares to IEPF
Glenmark’s consolidated revenue rises 7.96% to Rs. 27,674.89 Mn. for Q4 FY2019-20
Glenmark’s MDA Q4 FY 2019 – 20
Glenmark’s Q4 FY 2019-20 Results
Board Meeting Intimation – 26th June, 2020
Board Meeting Intimation – 26th June, 2020
Q4 FY20 Earnings Call Invitation – June 29, 2020
Glenmark initiates Phase 3 clinical trials on antiviral Favipiravir for COVID-19 patients in India
Glenmark introduces 3-in-1 inhaler therapy for COPD in India, promising reduction in risk of severe attacks and improvement in lung function
Glenmark receives approval from the regulator (DCGI) to conduct Clinical Trials in India on Favipiravir Antiviral tablets for COVID-19 patients
Glenmark Pharmaceuticals receives ANDA tentative approval for Dapagliflozin and Saxagliptin Tablets, 10 mg/5 mg
Glenmark Pharmaceuticals receives ANDA tentative approval for Dapagliflozin Tablets, 5 mg and 10 mg
Glenmark divests VWash, a female intimate hygiene wash, to Hindustan Unilever
Glenmark Pharmaceuticals and Hikma enter into an Exclusive Licensing Agreement for commercializing Ryaltris™ Seasonal Allergic Rhinitis Nasal Spray in the US
Newspaper Publication of Q3 FY 2019-20 Result
Glenmark’s consolidated revenue rises by 7.07% to Rs. 27,355.61 Mn. in Q3 FY 2019-20
Glenmark’s MDA Q3 FY 2019 – 20
Glenmark’s Q3 FY 2019-20 Results
Q3 FY20 Earnings Call Invitation – February 17, 2020
BM Notice Newspaper Publication – 14th February, 2020
Notice of Board Meeting - 31st January, 2020
About Us
Leading, integrated, global, research-led organization. Words which define us and our vision to discover a healthier future